Crystalline forms of quinazolinone compound and process for preparing the same
AssigneeCrystal Pharmatech Co., Ltd.
InventorsXiaoyu ZHANG, Zhixiong CHEN, Xia LU
Life of this patent
Estimating the term…
Abstract
Provided are a crystal form D, a crystal form AJ, a crystal form AL, a crystal form AZ, a crystal form AF, a crystal form Z and a crystal form AE of a compound of formula (I), a process for preparing the same and the use thereof. The crystal forms have advantages in at least one aspect of solubility, melting point, stability, dissolution, hygroscopicity, adhesiveness, fluidity, biological effectiveness, processability, purification effect, preparation production, safety, etc., thus providing a new better choice for the preparation of pharmaceutical preparations containing the compound of formula (I), and having important significance for drug development.
Claims19
A crystalline Form D of a compound, represented by formula (I), with a chemical name of 4-(7-hydroxy-4-oxo-2-propan-2-ylquinazolin-3-yl) benzonitrile, wherein, by using Cu-Kα radiation, the crystalline Form D has an X-ray powder diffraction pattern comprising characteristic peaks at the 2θ values of 6.7°±0.2°, 4.2°±0.2°,
3-13. (canceled)
A crystalline Form AE of a compound, represented by formula (I), with a chemical name of 4-(7-hydroxy-4-oxo-2-propan-2-ylquinazolin-3-yl) benzonitrile, wherein, by using Cu-Kα radiation, the crystalline Form AE has an X-ray powder diffraction pattern comprising characteristic peaks at the 2θ values of 12.6°±0.2°, 4.9°±0.2°, 14.0°±0.2°,
15-17. (canceled)
A crystalline Form of a compound, represented by formula (I), with a chemical name of 4-(7-hydroxy-4-oxo-2-propan-2-ylquinazolin-3-yl) benzonitrile, comprising crystalline Form AJ, crystalline Form AZ, or crystalline Form AF, wherein, by using Cu-Kα radiation,
- the crystalline Form AJ has an X-ray powder diffraction pattern comprising characteristic peaks at the 2θ values of 24.5°±0.2°, 14.0°±0.2°, 10.5°±0.2°;
- the crystalline Form AZ has an X-ray powder diffraction pattern comprising characteristic peaks at the 2θ values of 7.3°±0.2°, 7.9°±0.2°, 17.2°±0.2°;
- and
- the crystalline Form AF has an X-ray powder diffraction pattern comprising characteristic peaks at the 2θ values of 8.6°±0.2°, 10.0°±0,2°, 7.6°±0.2°,
The pharmaceutical composition of claim 28, wherein the pharmaceutical composition has an inhibitory activity on transient receptor potential vanilloid 1 (TPRV1).
Dependencies are inferred from the claim text.